Recombinant HIV1 Reverse Transcriptase protein (Active)
Be the first to review this product! Submit a review
|
(4 Publications)
Recombinant HIV1 Reverse Transcriptase protein (Active) is a HIV-1 M:B_HXB2R Full Length protein, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE, FuncS, ELISA, WB.
View Alternative Names
Gag-Pol polyprotein, Pr160Gag-Pol, gag-pol
- WB
Unknown
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (AB63979)
All lanes:
Western blot - Anti-HIV1 Reverse Transcriptase antibody (<a href='/en-us/products/primary-antibodies/hiv1-reverse-transcriptase-antibody-ab63911'>ab63911</a>) at 1/2500 dilution
All lanes:
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (ab63979) at 0.01 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-preadsorbed-ab97080'>ab97080</a>) at 1/5000 dilution
true
Exposure time: 90s
- WB
Unknown
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (AB63979)
All lanes:
Anti-HIV1 Reverse Transcriptase antibody [39/4.12.2] (<a href='/en-us/products/unavailable/hiv1-reverse-transcriptase-antibody-394122-ab9066'>ab9066</a>) at 1/2000 dilution
Lane 1:
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (ab63979) at 0.04 µg
Lane 2:
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (ab63979) at 0.02 µg
Lane 3:
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (ab63979) at 0.004 µg
Lane 4:
Western blot - Recombinant HIV1 Reverse Transcriptase protein (Active) (ab63979) at 0.002 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab6721'>ab6721</a>) at 1/5000 dilution
true
- SDS-PAGE
Unknown
SDS-PAGE - Recombinant HIV1 Reverse Transcriptase protein (Active) (AB63979)
Polyacrylamide gel electrophoresis of ab63979.
Reactivity data
Product details
ab63979 has been derived from infectious plasmid clone pNL4-3 and belongs to Group B of HIV-1.
Applications:
1) It is extremely effective for screening new specific inhibitors for HIV virus as a drug for treating AIDS.
2) Generally, Gag and Env proteins are employed as antigens for detecting anti-HIV-1 antibody. However, by using this enzyme in combination as an antigen, the detection will be more sensitive.
3) Reverse transcriptases are used in the first step of RT-PCR reaction for converting RNA to DNA. The HIV-1 reverse transcriptase can also be applied for RT-PCR method.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
HIV1 Reverse Transcriptase acts as a central player in the viral replication process by establishing an integrated provirus from the viral RNA genome. The enzyme is not part of a larger complex but works closely with other HIV-1 proteins such as integrase to facilitate the integration of the newly synthesized viral DNA into the host genome. This integration is a critical step in the viral life cycle and ensures the persistence of the virus in infected cells which then leads to the continuous production of new viral particles.
Pathways
HIV1 Reverse Transcriptase functions in the retroviral replication pathway. The enzyme's activity links intimately with other viral enzymes like HIV-1 integrase which assist in embedding the newly formed DNA into the host cell's DNA. This process aligns with the broader reverse transcription pathway including interactions with host cellular machinery that contribute to subsequent viral transcription and replication phases. Understanding these interactions helps in designing effective therapeutic strategies that target various stages of the HIV replication cycle.
Specifications
Form
Liquid
Additional notes
(CBB staining) Fractionated by step-wise ammonium sulfate precipitation.
General info
Function
Gag-Pol polyprotein. Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.. Matrix protein p17. Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).. Capsid protein p24. Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion (PubMed : 8648689). Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (PubMed : 12660176). Host restriction factors such as monkey TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (PubMed : 23785198). Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (PubMed : 24554657).. Nucleocapsid protein p7. Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates in gRNA dimerization, packaging, tRNA incorporation and virion assembly.. Protease. Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane (PubMed : 11932404, PubMed : 9573231). Cleavages take place as an ordered, step-wise cascade to yield mature proteins (PubMed : 11932404, PubMed : 9573231). This process is called maturation (PubMed : 11932404, PubMed : 9573231). Displays maximal activity during the budding process just prior to particle release from the cell (PubMed : 11932404, PubMed : 9573231). Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (PubMed : 7835426). Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (PubMed : 12660176, PubMed : 19914170). Also mediates cleavage of host YTHDF3 (PubMed : 32053707). Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (PubMed : 33542150).. Reverse transcriptase/ribonuclease H. Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.. Integrase. Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.
Post-translational modifications
Gag-Pol polyprotein. Specific enzymatic cleavages by the viral protease yield mature proteins. The protease is released by autocatalytic cleavage. The polyprotein is cleaved during and after budding, this process is termed maturation. Proteolytic cleavage of p66 RT removes the RNase H domain to yield the p51 RT subunit. Nucleocapsid protein p7 might be further cleaved after virus entry.. Matrix protein p17. Tyrosine phosphorylated presumably in the virion by a host kinase. Phosphorylation is apparently not a major regulator of membrane association (PubMed:17656588).. Capsid protein p24. Phosphorylated possibly by host MAPK1; this phosphorylation is necessary for Pin1-mediated virion uncoating.. Nucleocapsid protein p7. Methylated by host PRMT6, impairing its function by reducing RNA annealing and the initiation of reverse transcription.
Target data
Additional targets
Publications (4)
Recent publications for all applications. Explore the full list and refine your search
Molecular therapy. Methods & clinical development 26:394-412 PubMed36034773
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecules (Basel, Switzerland) 27: PubMed35458620
2022
Applications
Unspecified application
Species
Unspecified reactive species
Amino acids 52:1139-1147 PubMed32789611
2020
Applications
Unspecified application
Species
Unspecified reactive species
Proceedings of the National Academy of Sciences of 109:21450-5 PubMed23223527
2012
Applications
SDS-PAGE
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com